Zydus Lifesciences Limited has completed the acquisition of Agenus Inc.'s biologics manufacturing facilities in the United States and launched Zylidac Bio LLC to expand its presence in the U.S. market. Under the terms of the finalized agreements, Zydus will be the sole manufacturer for Agenus’ Phase 3 immuno-oncology candidates, botensilimab and balstilimab, and has secured exclusive rights to commercialize these assets in India and Sri Lanka. The transaction also includes a strategic collaboration, leveraging Agenus’ immunotherapy pipeline and Zydus’ global manufacturing and commercial infrastructure. This update follows the receipt of all necessary regulatory approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO64329) on January 15, 2026, and is solely responsible for the information contained therein.